C. Blake Simpson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
C. Blake Simpson has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Milan R. Amin
NYU Langone Medical Center
6 shared publications - Gregory N. Postma
Medical College of Georgia
2 shared publications Jeanne L. Hatcher
Department of Otolaryngology-Head and Neck Surgery, Emory University, Atlanta, Georgia, U.S.A.
2 shared publications- Laura M. Dominguez
Department of Otolaryngology Cleveland Clinic Florida Coral Springs Florida U.S.A.
2 shared publications Michael M. Johns
Department of Otolaryngology, University of Southern California, Los Angeles, California
2 shared publicationsAlbert L. Merati
Department of Otolaryngology–Head and Neck Surgery , University of Washington, Seattle, Washington
1 shared publication
Latest Publications
- 8 November 2018
- Published by Wiley in The Laryngoscope
- Vol. 129 (5) , 1155-1158
Subglottic stenosis: An evaluation of an elderly treatment‐seeking population
Objectives/Hypothesis To evaluate the demographics, etiology, intraoperative findings, and treatment outcomes of patients with subglottic stenosis (SGS), comparing those patients aged Laryngoscope, 2018
- 8 November 2018
- Published by Wiley in The Laryngoscope
- Vol. 129 (5) , 1155-1158
Subglottic stenosis: An evaluation of an elderly treatment‐seeking population
Objectives/Hypothesis To evaluate the demographics, etiology, intraoperative findings, and treatment outcomes of patients with subglottic stenosis (SGS), comparing those patients aged Laryngoscope, 2018
- 1 May 2017
- Published by Elsevier in Journal of Voice
- Vol. 31 (3) , 381.e1-381.e3
Mid-membranous Vocal Fold Webs: Case Series
- 1 May 2017
- Published by Elsevier in Journal of Voice
- Vol. 31 (3) , 381.e1-381.e3
Mid-membranous Vocal Fold Webs: Case Series
- 2 August 2016
- Published by Wiley in The Laryngoscope
- Vol. 127 (1) , 199-203
A novel approach to cricoarytenoid joint injections: An anatomic study
Objectives To demonstrate a novel approach to cricoarytenoid joint (CAJ) injections. Study Design Anatomic feasibility study. Methods Five human cadaveric larynges providing 10 CAJ s were used to obtain trajectory measurements of a 27-gauge 1½-inch needle placed between the CAJ capsule and the contralateral cricothyroid membrane. Ten additional larynges providing 20 CAJ s were then used to assess the efficacy of applying the previously obtained measurements to guide 0.2-cc methylene blue injections of the CAJ using a 27-gauge 1½-inch needle. Successful injection was confirmed by direct visualization of methylene blue within the CAJ capsule. Results The tip of the needle made a 70 ± 1.87 degree (confidence interval [CI] 95%) angle relative to the plane parallel to the anterior lamella of the cricoid cartilage; the needle was within the cricothyroid membrane 5 ± 0.77 mm (CI 95%) lateral to the midsagittal plane; the needle was 4 ± 0.80 mm (CI 95%) anteroinferior from the vocal process of the arytenoid cartilage as measured within the airway; and the distance from the point of airway entry and the CAJ capsule was 17 ± 2.42 mm (CI 95%). Twenty CAJ injections were attempted using the guidelines established here with an 85% success rate. Conclusion The current approach to CAJ injection utilizes microlaryngoscopy in an operative setting. This study is the first to describe the accessibility of the CAJ through percutaneous injection using reliable landmarks, potentially allowing access to the joint in an office-based setting. Level of Evidence NA Laryngoscope, 127:199–203, 2017
- 2 August 2016
- Published by Wiley in The Laryngoscope
- Vol. 127 (1) , 199-203
A novel approach to cricoarytenoid joint injections: An anatomic study
Objectives To demonstrate a novel approach to cricoarytenoid joint (CAJ) injections. Study Design Anatomic feasibility study. Methods Five human cadaveric larynges providing 10 CAJ s were used to obtain trajectory measurements of a 27-gauge 1½-inch needle placed between the CAJ capsule and the contralateral cricothyroid membrane. Ten additional larynges providing 20 CAJ s were then used to assess the efficacy of applying the previously obtained measurements to guide 0.2-cc methylene blue injections of the CAJ using a 27-gauge 1½-inch needle. Successful injection was confirmed by direct visualization of methylene blue within the CAJ capsule. Results The tip of the needle made a 70 ± 1.87 degree (confidence interval [CI] 95%) angle relative to the plane parallel to the anterior lamella of the cricoid cartilage; the needle was within the cricothyroid membrane 5 ± 0.77 mm (CI 95%) lateral to the midsagittal plane; the needle was 4 ± 0.80 mm (CI 95%) anteroinferior from the vocal process of the arytenoid cartilage as measured within the airway; and the distance from the point of airway entry and the CAJ capsule was 17 ± 2.42 mm (CI 95%). Twenty CAJ injections were attempted using the guidelines established here with an 85% success rate. Conclusion The current approach to CAJ injection utilizes microlaryngoscopy in an operative setting. This study is the first to describe the accessibility of the CAJ through percutaneous injection using reliable landmarks, potentially allowing access to the joint in an office-based setting. Level of Evidence NA Laryngoscope, 127:199–203, 2017
- 15 October 2015
- Published by Wiley in The Laryngoscope
- Vol. 126 (1) , 118-121
Botulinum toxin treatment of false vocal folds in adductor spasmodic dysphonia: Functional outcomes
Objectives/Hypothesis: Supraglottic injection of botulinum toxin (Botox) has been described as an effective treatment for adductor spasmodic dysphonia (ADSD). Anecdotal evidence suggests that the patients have little to no breathiness after injection, but no formal longitudinal studies have been carried out to date. The purpose of this study was to examine the voice outcomes in patients with ADSD after supraglottic Botox injection.Study Design: Retrospective case series.Methods: Patients with ADSD who were treated with supraglottic Botox injections completed a qualitative self‐evaluation of voice function after injection using the percentage of normal function (PNF) scale, a validated, quantitative scale from 0% (no function) to 100% (normal function). Posttreatment voice improvement after injection was determined using a Voice Handicap Index‐10 (VHI‐10) questionnaire.Results: A total of 198 supraglottic injections were performed between July 2011 and October 2014. Twenty‐five questionnaires were completed. Mean postinjection PNF was 95.0% ± 8.4% and was significantly increased from the preinjection mean PNF (62.5%) ± 22.6% (P < 0.001). The mean best VHI‐10 for all injections was 7.23. In 19 of 25 patients (76%), there was no reduction in PNF in the early postinjection period. In the remaining six patients (24%), the decline in mean vocal function was 9.2%.Conclusions: Supraglottic Botox injection is an effective treatment for ADSD. Postinjection voice is significantly improved, and the majority of patients do not experience breathy voice/decline in vocal function after injection.Level of Evidence: 4. Laryngoscope, 126:118–121, 2016
- 15 October 2015
- Published by Wiley in The Laryngoscope
- Vol. 126 (1) , 118-121
Botulinum toxin treatment of false vocal folds in adductor spasmodic dysphonia: Functional outcomes
Objectives/Hypothesis: Supraglottic injection of botulinum toxin (Botox) has been described as an effective treatment for adductor spasmodic dysphonia (ADSD). Anecdotal evidence suggests that the patients have little to no breathiness after injection, but no formal longitudinal studies have been carried out to date. The purpose of this study was to examine the voice outcomes in patients with ADSD after supraglottic Botox injection.Study Design: Retrospective case series.Methods: Patients with ADSD who were treated with supraglottic Botox injections completed a qualitative self‐evaluation of voice function after injection using the percentage of normal function (PNF) scale, a validated, quantitative scale from 0% (no function) to 100% (normal function). Posttreatment voice improvement after injection was determined using a Voice Handicap Index‐10 (VHI‐10) questionnaire.Results: A total of 198 supraglottic injections were performed between July 2011 and October 2014. Twenty‐five questionnaires were completed. Mean postinjection PNF was 95.0% ± 8.4% and was significantly increased from the preinjection mean PNF (62.5%) ± 22.6% (P < 0.001). The mean best VHI‐10 for all injections was 7.23. In 19 of 25 patients (76%), there was no reduction in PNF in the early postinjection period. In the remaining six patients (24%), the decline in mean vocal function was 9.2%.Conclusions: Supraglottic Botox injection is an effective treatment for ADSD. Postinjection voice is significantly improved, and the majority of patients do not experience breathy voice/decline in vocal function after injection.Level of Evidence: 4. Laryngoscope, 126:118–121, 2016
- 8 July 2015
- Published by Springer Nature in Current Otorhinolaryngology Reports
- Vol. 3 (3) , 138-143
Neurolaryngology: In-office Diagnosis and Treatment
- 8 July 2015
- Published by Springer Nature in Current Otorhinolaryngology Reports
- Vol. 3 (3) , 138-143
Neurolaryngology: In-office Diagnosis and Treatment
- 9 October 2014
- Published by SAGE Publications in Annals of Otology, Rhinology & Laryngology
- Vol. 124 (3) , 235-239
Voice Outcomes After Endoscopic Treatment of Laryngotracheal Stenosis
This study aimed to assess vocal disability in patients with laryngotracheal stenosis who are managed with endoscopic surgery, comparing patients with posterior glottic stenosis (PGS) to those with subglottic or tracheal stenosis (SGS/TS). Patients who underwent endoscopic treatment for laryngotracheal stenosis with voice outcomes data from 2005 to 2013 were studied. The mean Voice Handicap Index–10 (VHI-10) was compared over the study period. Of those with SGS/TS, the distance from the vocal folds to the proximal portion of the stenosis was obtained and compared to VHI-10. Forty-four patients met inclusion criteria. The mean VHI-10 for all patients was 14.6. Fifty percent were dysphonic (VHI-10 > 11). The mean VHI-10 for PGS patients was 22.4, and for SGS/TS patients, 10.9 (P = .004). Of those with PGS, 78.6% were dysphonic compared to only 36.7% of those with SGS/TS. Voice Handicap Index–10 improved from 14.1 for those with proximal stenosis to 4 for those with stenosis more than 2 cm distal to the vocal folds. Following endoscopic management of stenosis, those with PGS have poorer voice outcomes compared to those with SGS/TS. The majority of those with SGS/TS are not dysphonic. Vocal outcomes are greatest for those with stenosis beginning at least 2 cm distal to the vocal folds.
- 9 October 2014
- Published by SAGE Publications in Annals of Otology, Rhinology & Laryngology
- Vol. 124 (3) , 235-239
Voice Outcomes After Endoscopic Treatment of Laryngotracheal Stenosis
This study aimed to assess vocal disability in patients with laryngotracheal stenosis who are managed with endoscopic surgery, comparing patients with posterior glottic stenosis (PGS) to those with subglottic or tracheal stenosis (SGS/TS). Patients who underwent endoscopic treatment for laryngotracheal stenosis with voice outcomes data from 2005 to 2013 were studied. The mean Voice Handicap Index–10 (VHI-10) was compared over the study period. Of those with SGS/TS, the distance from the vocal folds to the proximal portion of the stenosis was obtained and compared to VHI-10. Forty-four patients met inclusion criteria. The mean VHI-10 for all patients was 14.6. Fifty percent were dysphonic (VHI-10 > 11). The mean VHI-10 for PGS patients was 22.4, and for SGS/TS patients, 10.9 (P = .004). Of those with PGS, 78.6% were dysphonic compared to only 36.7% of those with SGS/TS. Voice Handicap Index–10 improved from 14.1 for those with proximal stenosis to 4 for those with stenosis more than 2 cm distal to the vocal folds. Following endoscopic management of stenosis, those with PGS have poorer voice outcomes compared to those with SGS/TS. The majority of those with SGS/TS are not dysphonic. Vocal outcomes are greatest for those with stenosis beginning at least 2 cm distal to the vocal folds.
- 25 July 2012
- Published by Springer Nature
- p. 911-927
Vocal Fold Medialization, Arytenoid Adduction, and Partial Pharyngectomy
- 25 July 2012
- Published by Springer Nature
- p. 911-927
Vocal Fold Medialization, Arytenoid Adduction, and Partial Pharyngectomy
- 25 April 2011
- Published by Wiley in The Laryngoscope
- Vol. 121 (5) , 1023-1026
Idiopathic ulcerative laryngitis
Objectives/Hypothesis: Idiopathic ulcerative laryngitis (IUL) is a distinct, clinical entity that presents after a prolonged upper respiratory infection with cough. It is characterized by the development of bilateral ulcerations of the mid‐membranous vocal folds followed by a protracted course of healing. The purpose of this review was to characterize the typical patient presentation, clinical findings, and prognosis.Study Design: Multi‐institutional retrospective reviewMethods: Retrospective review of charts and videostroboscopic exams from patients with IUL at eight institutions.Results: Fifteen cases met the criteria for IUL and were included in the study. The mean age of the patients was 49 years, and 93% were female. All patients were nonsmokers. Multiple medical interventions were employed by the treating otolaryngologist during the course of the disease, none of which resulted in acute resolution of the ulcerations. The average time from initial presentation to resolution of the disease was 3.3 months. All of the patients reported that their voice was improved after resolution of the disease process. However, in the majority of the patients (60%) there were persistent vibratory abnormalities after resolution of the ulcerations.Conclusions: This is the first multi‐institutional study to define the complete disease course of IUL and to establish diagnostic criteria. IUL is a rare yet well‐recognized clinical entity; however, there is no established etiology for this condition and no definitive treatments have emerged. Further study is needed to establish the etiology/risk factors of this condition and to determine optimal medical management.
- 25 April 2011
- Published by Wiley in The Laryngoscope
- Vol. 121 (5) , 1023-1026
Idiopathic ulcerative laryngitis
Objectives/Hypothesis: Idiopathic ulcerative laryngitis (IUL) is a distinct, clinical entity that presents after a prolonged upper respiratory infection with cough. It is characterized by the development of bilateral ulcerations of the mid‐membranous vocal folds followed by a protracted course of healing. The purpose of this review was to characterize the typical patient presentation, clinical findings, and prognosis.Study Design: Multi‐institutional retrospective reviewMethods: Retrospective review of charts and videostroboscopic exams from patients with IUL at eight institutions.Results: Fifteen cases met the criteria for IUL and were included in the study. The mean age of the patients was 49 years, and 93% were female. All patients were nonsmokers. Multiple medical interventions were employed by the treating otolaryngologist during the course of the disease, none of which resulted in acute resolution of the ulcerations. The average time from initial presentation to resolution of the disease was 3.3 months. All of the patients reported that their voice was improved after resolution of the disease process. However, in the majority of the patients (60%) there were persistent vibratory abnormalities after resolution of the ulcerations.Conclusions: This is the first multi‐institutional study to define the complete disease course of IUL and to establish diagnostic criteria. IUL is a rare yet well‐recognized clinical entity; however, there is no established etiology for this condition and no definitive treatments have emerged. Further study is needed to establish the etiology/risk factors of this condition and to determine optimal medical management.
- 1 January 2011
- Published by Elsevier
- p. 91-104
Surgery for Unilateral Vocal Fold Paralysis
- 21 July 2009
- Published by Wiley in The Laryngoscope
- Vol. 119 (8) , 1652-1657
Laryngeal complications after lipoinjection for vocal fold augmentation
Objectives/Hypothesis: Vocal fold augmentation with autologous fat has been widely used for the last 15 years with varying success. Autologous fat is biocompatible, readily available, and easily harvested, making it a commonly used material for vocal fold augmentation. Although felt to be a relatively safe procedure, few studies have looked at the complication rate of lipoinjection for vocal fold augmentation.Study Design: Retrospective review.Methods: Ninety‐eight vocal fold injections were performed at one institution from 1997 to 2008. The charts were reviewed retrospectively, and age, diagnosis, side of procedure, concurrent procedures, length of follow‐up, and complications during or subsequent to the injection were recorded in a database. Patients were excluded if data was inadequate to make a determination regarding complication during or after lipoinjection.Results: Eighty‐eight patients met the criteria for review with an average age of 57.4 years. The most common indications for injection were vocal fold paresis, vocal fold scarring, and presbylaryngeus. Mean follow‐up was 20.2 months with a range of 0 months to 126 months. Overall, four laryngeal complications occurred (4.5%), including three over‐injections (3.4%) leading to poor voice quality and one granuloma formation (1.1%). The over‐injections were managed using cordotomy with fat removal, resulting in vocal improvement in all cases.Conclusions: Although lipoinjection vocal fold augmentation is a safe procedure, over‐injection of autologous fat is a risk. Lipoinjection for vocal fold augmentation can lead to over‐injection with dysphonia in a small number of patients. The complications can be managed with lateral cordotomy and fat removal.
- 21 July 2009
- Published by Wiley in The Laryngoscope
- Vol. 119 (8) , 1652-1657
Laryngeal complications after lipoinjection for vocal fold augmentation
Objectives/Hypothesis: Vocal fold augmentation with autologous fat has been widely used for the last 15 years with varying success. Autologous fat is biocompatible, readily available, and easily harvested, making it a commonly used material for vocal fold augmentation. Although felt to be a relatively safe procedure, few studies have looked at the complication rate of lipoinjection for vocal fold augmentation.Study Design: Retrospective review.Methods: Ninety‐eight vocal fold injections were performed at one institution from 1997 to 2008. The charts were reviewed retrospectively, and age, diagnosis, side of procedure, concurrent procedures, length of follow‐up, and complications during or subsequent to the injection were recorded in a database. Patients were excluded if data was inadequate to make a determination regarding complication during or after lipoinjection.Results: Eighty‐eight patients met the criteria for review with an average age of 57.4 years. The most common indications for injection were vocal fold paresis, vocal fold scarring, and presbylaryngeus. Mean follow‐up was 20.2 months with a range of 0 months to 126 months. Overall, four laryngeal complications occurred (4.5%), including three over‐injections (3.4%) leading to poor voice quality and one granuloma formation (1.1%). The over‐injections were managed using cordotomy with fat removal, resulting in vocal improvement in all cases.Conclusions: Although lipoinjection vocal fold augmentation is a safe procedure, over‐injection of autologous fat is a risk. Lipoinjection for vocal fold augmentation can lead to over‐injection with dysphonia in a small number of patients. The complications can be managed with lateral cordotomy and fat removal.